AveXis to Host Webcast Update of Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
October 10 2016 - 7:00AM
-- Data, Including Developmental Milestones, as
of September 15, 2016 as presented by Jerry Mendell, M.D. at the
International Annual Congress of the World Muscle Society --
AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company
developing treatments for patients suffering from rare and
life-threatening neurological genetic diseases, will host a live
webcast briefing regarding data as of September 15, 2016, including
developmental milestone achievements, from the ongoing Phase 1
clinical trial of AVXS-101 in Spinal Muscular Atrophy (SMA) Type 1
as presented by Jerry Mendell, M.D., director of the Center for
Gene Therapy at The Research Institute at Nationwide Children’s
Hospital, during the Late Breaking Session at the 21st
International Annual Congress of the World Muscle Society in
Granada, Spain.
The webcast will take place today, Monday, October 10, 2016 at
8:30 a.m. EDT. Analysts and investors can participate in the
conference call by dialing (844) 889-6863 for domestic callers and
(661) 378-9762 for international callers, using the conference ID
93427499. The webcast can be accessed live on the Events and
Presentations page in the Investors and Media section of the AveXis
website, www.AveXis.com. The webcast will be archived on the
company’s website for 5 days and will be available for telephonic
replay for 14 days following the call by dialing (855) 859-2056
(Domestic) or (404) 537-3406 (International), conference ID
93427499.
About SMASMA is a severe neuromuscular disease
characterized by the loss of motor neurons leading to progressive
muscle weakness and paralysis. SMA is caused by a genetic defect in
the SMN1 gene that codes SMN, a protein necessary for survival of
motor neurons. The incidence of SMA is approximately one in 10,000
live births.
The most severe form of SMA is Type 1, a lethal genetic disorder
characterized by motor neuron loss and associated muscle
deterioration, which results in mortality or the need for permanent
ventilation support before the age of two for greater than 90
percent of patients. SMA Type 1 is the leading genetic cause of
infant mortality.
About AVXS-101AVXS-101 is a proprietary gene
therapy candidate of a one-time treatment for SMA Type 1 and is the
only clinical-stage gene therapy in development for SMA. AVXS-101
is designed to address the monogenetic root cause of SMA and
prevent further muscle degeneration by addressing the defective
and/or loss of the primary SMN gene. AVXS-101 also targets motor
neurons providing rapid onset of effect, and crosses the blood
brain barrier allowing an IV dosing route and effective targeting
of both central and systemic features.
About AveXis, Inc.AveXis is a clinical-stage
gene therapy company developing treatments for patients suffering
from rare and life-threatening neurological genetic diseases. The
company’s initial proprietary gene therapy candidate, AVXS-101, is
in an ongoing Phase 1 clinical trial for the treatment of SMA Type
1. For additional information, please visit www.avexis.com.
Media Inquiries:
Lauren Barbiero
W2O Group
646-564-2156
lbarbiero@w2ogroup.com
Investor Inquiries:
Jim Goff
AveXis, Inc.
650-862-4134
jgoff@avexis.com
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jul 2023 to Jul 2024